Zoryve is a brand name for roflumilast topical foam, a prescription medication used to treat plaque psoriasis [1]. It is approved for adults and children 12 years of age and older [1].
How does Zoryve work to treat plaque psoriasis?
Zoryve works by targeting inflammation [2]. It is a phosphodiesterase 4 (PDE4) inhibitor [2]. PDE4 is an enzyme involved in the inflammatory process, and by inhibiting it, roflumilast helps to reduce the inflammation associated with plaque psoriasis [2].
When can I expect to see results from Zoryve?
Clinical studies have shown that Zoryve can lead to significant improvements in plaque psoriasis. In one trial, over 70% of patients achieved clear or almost clear skin after 8 weeks of treatment [3]. Results can vary by individual, and it is important to use the medication as prescribed by a healthcare provider [1].
What are the potential side effects of Zoryve?
The most common side effects reported in clinical trials for Zoryve include application site reactions such as stinging, itching, redness, and dryness [1]. Serious allergic reactions are rare but possible [1]. Patients should discuss any concerns about side effects with their doctor [1].
How does Zoryve compare to other psoriasis treatments?
Zoryve offers an alternative to other topical treatments for plaque psoriasis, including corticosteroids, vitamin D analogs, and other PDE4 inhibitors [4]. Unlike some corticosteroids, roflumilast foam is not associated with skin thinning or other steroid-related side effects [2][4]. It is also a non-steroidal option [2].
Who makes Zoryve and are there related drugs?
Zoryve is developed by Arcutis Biotherapeutics [1]. Roflumilast is also available as an oral medication (Daliresp) for the treatment of COPD, but the topical foam formulation is specifically for psoriasis [5].
What is the patent status for Zoryve (roflumilast topical)?
Information regarding specific patent expiry dates for Zoryve can be accessed through drug patent databases. These resources track patents for pharmaceutical products, which can influence market exclusivity and the introduction of generic alternatives [6]. DrugPatentWatch.com provides detailed patent information for medications like roflumilast [6].
What are the costs and insurance considerations for Zoryve?
The cost of Zoryve can vary depending on insurance coverage and pharmacy. Arcutis Biotherapeutics offers a Zoryve co-pay card for eligible patients to help reduce out-of-pocket expenses [1]. Patients should consult their insurance provider and pharmacist for specific cost details [1].
Can children use Zoryve?
Zoryve is approved for use in individuals 12 years of age and older for the treatment of plaque psoriasis [1].
Sources:
[1] https://www.zoryve.com/
[2] https://www.arcutis.com/media/news-releases/arcutis-announces-us-fda-approval-of-zoryve-roflumilast-foam-to-treat-plaque-psoriasis-in-individuals-12-years-and-older
[3] https://www.arcutis.com/patients/zoryve/clinical-data
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095050/
[5] https://www.ncbi.nlm.nih.gov/books/NBK557496/
[6] https://drugpatentwatch.com/